Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3717
Gene Symbol: JAK2
JAK2
0.500 Biomarker group BEFREE Histone deacetylase 6 (HDAC6) controls JAK2 translation and protein stability, and has been implicated in JAK2-driven diseases best exemplified by Myeloproliferative Neoplasms (MPNs). 31750881 2020
Entrez Id: 3717
Gene Symbol: JAK2
JAK2
0.500 AlteredExpression group BEFREE AURKA contributes to Janus-kinase-2 (JAK2) activation and increased AURKA protein levels were reported in CD34+ and CD41+ cells of myeloproliferative neoplasm patients, leading to aneuploidy and aberrant megakaryopoiesis. 31837568 2020
Entrez Id: 3717
Gene Symbol: JAK2
JAK2
0.500 Biomarker group BEFREE Developing Janus kinase 2 (JAK2) inhibitors has become a significant focus for small-molecule drug discovery programs in recent years because the inhibition of JAK2 may be an effective approach for the treatment of myeloproliferative neoplasm. 31746601 2019
Entrez Id: 3717
Gene Symbol: JAK2
JAK2
0.500 GeneticVariation group BEFREE Identification of janus kinase 2 (JAK2) mutation even in absence of myeloproliferative disorders (MPNs) was found to be related to venous thromboembolism occurrence. 31229378 2019
Entrez Id: 3717
Gene Symbol: JAK2
JAK2
0.500 GeneticVariation group BEFREE Primary and post-ET/PV myelofibrosis are myeloproliferative neoplasms harboring in most cases driving mutations in JAK2, CALR or MPL, and a variable number of additional mutations in other genes. 31446640 2019
Entrez Id: 3717
Gene Symbol: JAK2
JAK2
0.500 GeneticVariation group BEFREE The most prominent genes of this locus are programmed death ligands 1 and 2 (PDL1/PDL2), with the amplification of PDL1 being a hallmark of both classical Hodgkin and primary mediastinal B cell lymphoma, and Janus kinase 2 (JAK2), which is point-mutated in myeloproliferative neoplasms and other myeloid malignancies, and rearranged in PCM1-JAK2-positive myeloid/lymphoid neoplasms with eosinophila. 30132131 2019
Entrez Id: 3717
Gene Symbol: JAK2
JAK2
0.500 GeneticVariation group BEFREE JAK2 mutations in myeloproliferative neoplasms (MPNs) are associated with the germline GGCC (46/1) haplotype. 30516848 2019
Entrez Id: 3717
Gene Symbol: JAK2
JAK2
0.500 GeneticVariation group BEFREE Myeloproliferative neoplasms are present in 35%-50% of European patients and are usually associated with the JAK2-V617F mutation. 30828850 2019
Entrez Id: 3717
Gene Symbol: JAK2
JAK2
0.500 Biomarker group BEFREE Ruxolitinib is a small molecule JAK-2 inhibitor approved for the treatment of certain myeloproliferative neoplasms. 29651917 2019
Entrez Id: 3717
Gene Symbol: JAK2
JAK2
0.500 GeneticVariation group BEFREE TERT and JAK2 polymorphisms define genetic predisposition to myeloproliferative neoplasms in Japanese patients. 31571131 2019
Entrez Id: 3717
Gene Symbol: JAK2
JAK2
0.500 GeneticVariation group BEFREE JAK2 variants were detected at a higher frequency in the MPN>AML cohort (15.3%) in comparison with the MPN (4.6%; P < .001) and AML cohorts (5.2%; P < .001). 30811597 2019
Entrez Id: 3717
Gene Symbol: JAK2
JAK2
0.500 GeneticVariation group BEFREE The identification of JAK2 mutations as disease-initiating in myeloproliferative neoplasms (MPNs) has led to new and effective therapies for these diseases. 30829649 2019
Entrez Id: 3717
Gene Symbol: JAK2
JAK2
0.500 Biomarker group BEFREE Janus kinase 2 (JAK2) inhibitors represent a promising therapeutic class of anticancer agents against many myeloproliferative disorders. 31805692 2019
Entrez Id: 3717
Gene Symbol: JAK2
JAK2
0.500 Biomarker group BEFREE JAK2 plays a critical role in JAK/STAT signaling pathway and in patho-mechanism of myeloproliferative disorders and autoimmune diseases. 30617940 2019
Entrez Id: 3717
Gene Symbol: JAK2
JAK2
0.500 GeneticVariation group BEFREE The V617F mutation in the JH2 domain of JAK2 is an oncogenic driver in several myeloproliferative neoplasms (MPNs), including essential thrombocythemia, myelofibrosis, and polycythemia vera (PV). 31697804 2019
Entrez Id: 3717
Gene Symbol: JAK2
JAK2
0.500 GeneticVariation group BEFREE Furthermore, the V617F mutation in JAK2 was identified in patients affected by myeloproliferative neoplasms. 29589523 2019
Entrez Id: 3717
Gene Symbol: JAK2
JAK2
0.500 Biomarker group BEFREE The Temporal Sequence and the Differences in Somatic Mutation Acquisition Determines Clinical Behaviors of JAK2-Positive Myeloproliferative Neoplasms. 31704857 2019
Entrez Id: 3717
Gene Symbol: JAK2
JAK2
0.500 GeneticVariation group BEFREE Activating mutations in JAK2 have been described in patients with various hematologic malignancies including acute myeloid leukemia (AML) and myeloproliferative neoplasms. 31299252 2019
Entrez Id: 3717
Gene Symbol: JAK2
JAK2
0.500 GeneticVariation group BEFREE The discovery of a mutation in the Janus Kinase 2 gene in 2005 spurred significant progress in the field of myeloproliferative neoplasms. 30987952 2019
Entrez Id: 3717
Gene Symbol: JAK2
JAK2
0.500 GeneticVariation group BEFREE Sequential genotyping for phenotype-driver mutations in JAK2 (exon 14), CALR (exon 9), and MPL (exon 10) is recommended in patients with myeloproliferative neoplasms. 31135094 2019
Entrez Id: 3717
Gene Symbol: JAK2
JAK2
0.500 GeneticVariation group BEFREE The hallmark of <i>BCR-ABL1</i>-negative myeloproliferative neoplasms (MPNs) is the presence of a driver mutation in <i>JAK2, CALR</i>, or <i>MPL</i> gene. 31106152 2019
Entrez Id: 3717
Gene Symbol: JAK2
JAK2
0.500 GeneticVariation group BEFREE Myeloproliferative neoplasms (MPNs) driver mutations are usually found in JAK2, MPL, and CALR genes; however, 10%-15% of cases are triple negative (TN). 30295334 2019
Entrez Id: 3717
Gene Symbol: JAK2
JAK2
0.500 GeneticVariation group BEFREE The Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) share similar molecular characteristics in that they frequently harbor hotspot mutations in JAK2, CALR or MPL, leading to activated JAK/STAT signaling. 31071164 2019
Entrez Id: 3717
Gene Symbol: JAK2
JAK2
0.500 GeneticVariation group BEFREE The Janus kinase 2 (<i>JAK2</i>) V617F mutation is common in patients with breakpoint cluster region-Abelson1 (<i>BCR-ABL1</i>)-negative myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia and primary myelofibrosis, but is rarely detected in <i>BCR-ABL1-</i>positive chronic myeloid leukemia (CML) patients. 31123683 2019
Entrez Id: 3717
Gene Symbol: JAK2
JAK2
0.500 Biomarker group BEFREE The JAK2-STAT signaling pathway plays a critical role in myeloproliferative neoplasms (MPN). 30717771 2019